XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the CountryPRNewsWire • 07/05/24
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 07/01/24
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South KoreaPRNewsWire • 06/26/24
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesPRNewsWire • 06/01/24
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferencePRNewsWire • 05/08/24
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029PRNewsWire • 05/08/24
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressPRNewsWire • 05/08/24
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingPRNewsWire • 04/24/24
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesPRNewsWire • 03/06/24
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/29/24
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressPRNewsWire • 02/29/24
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024PRNewsWire • 02/22/24
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/14/24
Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)Seeking Alpha • 02/05/24
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug ListPRNewsWire • 12/14/23
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)PRNewsWire • 12/11/23